EURAND

Eurand N.V. (Eurand) is a holding company. The Company is a specialty pharmaceutical company that develops, manufactures and commercializes pharmaceutical and biopharmaceutical products. The Company is commercializing a portfolio of products for cystic fibrosis (CF) and gastrointestinal (GI) patients in the United States. As of December 31, 2009, it had two late-stage product candidates, EUR-1073 (beclomethasone) and EUR-1025 (ondansetron) in development in its own portfolio, as well as a number of other products in development with collaboration partners, including EUR-1000, which is partnered with GlaxoSmithKline (GSK). It has manufacturing and research facilities in the United States, Italy and France.